SCHEMBL2947154

SCHEMBL2947154

NS(=O)(=O)c1ccc(Nc2ccccc2Sc2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.65
▸ TDP1 Q9NUW8 2/20 0.65
▸ POLB P06746 2/20 0.65
▸ DOT1L Q8TEK3 1/20 0.55
▸ BCL2L1 Q07817 1/20 0.49
▸ GAA P10253 3/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ PKM P14618 3/20 0.46
▸ WNK1 Q9H4A3 1/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ CA12 O43570 2/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ CA2 P00918 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9487112 0.79 MAPT (1.00) MAPTTDP1POLBDOT1LGAA
SCHEMBL29699504 0.79 MAPT (1.00) MAPTTDP1POLBDOT1LGAA
SCHEMBL2949010 0.76 MAPT (0.65) MAPTTDP1POLBDOT1LGAA
SCHEMBL2950572 0.76 BCL2L1 (0.68) BCL2L1ALDH1A1L3MBTL1
SCHEMBL1113832 0.74 BCL2L1 (0.64) MAPTTDP1POLBDOT1LBCL2L1
SCHEMBL9454177 0.72 MAPT (0.66) MAPTTDP1POLBDOT1LGAA
SCHEMBL2943101 0.71 MAPT (0.55) MAPTTDP1POLBDOT1LBCL2L1
SCHEMBL2946318 0.71 MAPT (0.55) MAPTTDP1POLBDOT1LBCL2L1
SCHEMBL1542077 0.71 MAPT (0.58) MAPTTDP1POLBDOT1LBCL2L1
SCHEMBL1911607 0.71 MAPT (0.71) MAPTTDP1POLBDOT1LGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 — — US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 — — US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 — — US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 — — US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885TDP1 1063/4885POLB 1110/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4830/4885TDP1 1246/4885POLB 859/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885TDP1 1063/4885POLB 1110/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR MAPT 4806/4885TDP1 2123/4885POLB 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback